346603-68-7

Basic information

• Product Name: Methyl 2-bromomethyl-3-trifluoromethyl benzoate
• Synonyms: Methyl 2-bromomethyl-3-trifluoromethyl benzoate
• CAS NO: 346603-68-7
• Molecular Formula: C₁₀H₈BrF₃O₂
• Molecular Weight: 297.0685296
• Mol File: 346603-68-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 2-bromomethyl-3-trifluoromethyl benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-bromomethyl-3-trifluoromethyl benzoate(346603-68-7)
• EPA Substance Registry System: Methyl 2-bromomethyl-3-trifluoromethyl benzoate(346603-68-7)

Safety Data

• Hazardous Substances Data: 346603-68-7(Hazardous Substances Data)

Upstream product

• 346603-63-2 methyl 2-methyl-3-(trifluoromethyl)benzoate 
• 62089-35-4 2-methyl-3-(trifluoromethyl)benzoic acid 

Downstream Products

• 1407232-94-3 (S)-4-methylsulfanyl-2-(1-oxo-4-trifluoromethyl-1,3-dihydro-isoindol-2-yl)-butyric acid methyl ester 

Relevant articles and documents

Pyridazone derivative and its uses

The present invention belongs to the pharmaceutical field, specifically relates to a pyridazone derivative and its uses, compounds thereof and pharmaceutically acceptable salts, solvates including hydrates, polycrystallines, prodrugs, co-crystallines, tau

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

A series of analogs of the immunomodulary drugs lenalidomide (1) and pomalidomide (2), in which the amino group is replaced with various isosteres, was prepared and assayed for immunomodulatory activity and activity against cancer cell lines. The 4-methyl and 4-chloro analogs 4 and 15, respectively, displayed potent inhibition of tumor necrosis factor-α (TNF-α) in LPS-stimulated hPBMC, potent stimulation of IL-2 in a human T cell co-stimulation assay, and anti-proliferative activity against the Namalwa lymphoma cell line. Both of these analogs displayed oral bioavailability in rat.

Tricyclic compounds

The present invention is to provide novel tricyclic compounds having leukotriene antagonistic action and represented by the formula: wherein R1 represents a halogen atom, etc., R2 represents a nitro group, etc., A represents a 5-membered or a 6-membered heteroaromatic ring group containing 1 to 3 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, etc., B represents a formula: —OCH2—, etc., X represents a sulfur atom, etc., Y represents C1-C10 alkylene group which may have a halogen atom, etc. as a substituent(s), Z represents a carboxyl group whic may be protected, etc., represents a single bond or a double bond, m is an integer of 1 to 4, n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof.